Subscribe to RSS
DOI: 10.1055/s-0038-1660792
Erratum to: A Double-Blind, Randomized, Placebo-Controlled Trial of 17 Alpha-hydroxyprogesterone Caproate in the Management of Preterm Premature Rupture of Membranes
Publication History
Publication Date:
20 June 2018 (online)
It has been brought to the publisher's attention there were some errors in [Table 3] in the above article in the American Journal of Perinatology, published online on February 8, 2018 (DOI: 10.1055/s-0037-1617428). The correct table appears as follows:
Placebo (n = 11) |
17-OHPC (n = 10) |
p-Value |
|
---|---|---|---|
Birth weight, g |
1,220 (969–1,558) |
1,493 (1,124–1,903) |
0.35 |
5-min Apgar < 7 |
1 |
2 |
0.59 |
Cord artery pH[b] |
7.29 (0.03) |
7.25 (0.02) |
0.14 |
Neonatal death |
0 |
1 |
0.48 |
Culture-proven sepsis |
1 |
4 |
0.15 |
RDS |
10 |
8 |
0.59 |
IVH grades III–IV |
2 |
1 |
>0.99 |
NEC |
1 |
0 |
1.0 |
Days admitted postbirth[c] |
50 (34–69) |
39 (13–59) |
0.16 |
Abbreviations: 17-OHPC, 17 α-hydroxyprogesterone caproate; IVH, intraventricular hemorrhage; NEC, necrotizing enterocolitis; RDS, respiratory distress syndrome.
a Data reported as n or median (95% confidence interval) unless otherwise noted.
b Data missing from two women from each group; data are mean, standard error of the mean.
c Data missing from one infant as the infant was transferred to an outside hospital for insurance-related issues.